비교리스트

 카트 문의
시장보고서
상품코드
1701637

케티아핀 중간 화학물질 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Quetiapine Intermediate Chemicals Market Size, Share & Trends Analysis Report By Product (1-[2-(2-Hydroxyethoxy)ethyl] Piperazine, Dibenzo[b,f][1,4]thiazepin 11 (10 H)-one), By End-use, By Region, And Segment Forecasts, 2025 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 80 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

케티아핀 중간 화학물질 시장 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 케티아핀 중간 화학물질 시장 규모는 2030년까지 658억 달러에 이르며, 2025년부터 2030년까지의 CAGR은 4.9%를 나타낼 것으로 예측됩니다.

주요 촉진요인은 정신질환의 세계 발생률 상승, 케티아핀 수요 증가, 따라서 그 중간체의 필요성입니다.

정신 분열증과 양극성 장애와 같은 정신 질환의 세계의 부담은 중요한 촉진요인입니다. 인지도와 진단의 향상은 케티아핀과 같은 효과적인 치료제에 대한 수요 증가에 기여하고 있습니다.

선발품인 케티아핀의 특허가 끊어진 것으로, 제네릭 의약품 제조업체에 시장이 개방되었습니다. 제약회사는 서방형 제제나 새로운 딜리버리 시스템 등 케티아핀의 새로운 제제를 지속적으로 연구개발하고 있습니다.

정신 질환의 유병률 증가는 케티아핀에 대한 의약품 수요를 직접적으로 촉진하기 때문에 중간체 화학의 필요성을 높입니다. 비용 효율적인 제네릭 의약품 제조의 추진으로 제약 회사는 이러한 중간체를 효율적으로 조달해야 한다고 강요하고 있습니다. 신규 케티아핀 제제 및 전달 시스템에 중점을 둔 의약품의 R&D 노력은 이러한 중요한 화학 성분 수요 증가에 더욱 기여하고 있습니다.

아시아태평양에서는 헬스케어 지출 증가와 정신질환 유병률의 상승을 배경으로 의약품 부문이 급성장하고 있으며, 케티아핀 수요를 크게 밀어 올리고 있습니다. 이 지역에서는 저렴한 의약품 제공을 목적으로 한 제네릭 의약품 제조에 주력하고 있으며, 비용 효율적인 케티아핀 중간체의 필요성이 직접적으로 높아지고 있습니다. 또한 APAC 전역에서 현지 의약품 연구개발에 대한 투자가 증가하고 있는 것도 이 중요한 화학 전구체 수요 증가에 기여하고 있습니다.

케티아핀 중간 화학물질 시장 보고서 하이라이트

  • 최종 용도에 따르면 의약품 부문이 2024년에 85.5%의 최대 수익 점유율을 차지했습니다. 정신분열증과 양극성 장애와 같은 정신질환의 유병률이 증가하고 있다는 것은 케티아핀 수요 증가를 촉진하고, 그 결과 중간체 화학물질의 요구가 높아지고 있습니다.
  • 제품별로는 디벤조(b, f)(1,4) 티아제핀 11(10H)-온 부문이 2024년에 35.2%의 최대 수익 점유율을 차지했으며 예측 기간 동안에도 업계를 지배할 것으로 예측됩니다. 이것은 케티아핀 합성의 기본적인 중간체이며, 핵심이 되는 고리 구조를 형성합니다. 그 생산 효율은 케티아핀의 생산량에 직접 영향을 미치므로 모든 업스트림 중간체 수요에 영향을 미칩니다.
  • 지역별로는 아시아태평양이 2024년 매출액 점유율 50.7%를 차지했습니다.
  • 2024년 12월, 아미 오가닉스사는 중국 하북성의 창저우 공장에서 다기능 첨가제 Nylostab S-EED를 제조하기 위한 제2제조 라인의 건설을 개시했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향, 범위

  • 세계의 케티아핀 중간 화학물질 시장 전망
  • 밸류체인 분석
    • 원재료 전망
    • 산업용 냉동기/제품 전망
    • 판매 채널 분석
  • 가격 동향 분석
    • 가격에 영향을 미치는 요인
  • 규제 프레임워크
    • 표준 및 규정 준수
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
    • 시장 과제 분석
    • 시장 기회 분석
  • Porter's Five Forces 분석
    • 공급기업의 협상력
    • 구매자의 협상력
    • 대체 위협
    • 신규 참가업체의 위협
    • 경쟁 기업간 경쟁 관계
  • PESTLE 분석
    • 정치
    • 경제
    • 사회 환경
    • 제품
    • 환경
    • 법률

제4장 케티아핀 중간 화학물질 시장 : 제품별 추정 및 동향 분석

  • 케티아핀 중간 화학물질 시장 : 제품별 변동 분석(2024년, 2030년)
  • 1-(2-(2-히드록시에톡시)에틸)피페라진
  • 디벤조(b,f)(1,4)티아제핀11(10H)-원
  • 기타 제품

제5장 케티아핀 중간 화학물질 시장 : 최종 용도별 추정 및 동향 분석

  • 케티아핀 중간 화학물질 시장 : 최종 용도별 변동 분석(2024년, 2030년)
  • 제약
  • 기타 용도

제6장 케티아핀 중간 화학물질 시장 : 지역별 추정 및 동향 분석

  • 지역별 분석(2024년, 2030년)
  • 북미
    • 제품별(2018-2030년)
    • 최종 용도별(2018-2030년)
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 제품별(2018-2030년)
    • 최종 용도별(2018-2030년)
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
  • 아시아태평양
    • 제품별(2018-2030년)
    • 최종 용도별(2018-2030년)
    • 중국
    • 인도
    • 일본
    • 한국
  • 라틴아메리카
    • 제품별(2018-2030년)
    • 최종 용도별(2018-2030년)
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 제품별(2018-2030년)
    • 최종 용도별(2018-2030년)
    • 사우디아라비아
    • 남아프리카

제7장 경쟁 구도

  • 주요 시장 진출기업의 최근 동향
  • 기업 분류
  • 기업 히트맵 분석
  • 기업의 시장 포지셔닝 분석(2024년)
  • 전략 매핑
  • 기업 프로파일/목록
    • Merck KGaA
    • Shreeneel Chemicals
    • Emeron Electric Co.
    • Luye Pharma Group
    • Argana Group
    • IOL Chemicals &Pharmaceuticals Ltd
    • AR Lifesciences
    • ALLCHEM LIFESCIENCE PVT. LTD.
    • AstraZeneca
    • Shreeneel Chemicals
    • Aether Industries
KTH

Quetiapine Intermediate Chemicals Market Growth & Trends:

The global quetiapine intermediate chemicals market size is anticipated to reach USD 65.8 billion by 2030 and is anticipated to grow at a CAGR of 4.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The primary driver is the rising global incidence of mental health disorders, increasing quetiapine demand, and thus the need for its intermediates. The cost-effectiveness of generic quetiapine production, especially in emerging markets, directly fuels demand for efficient intermediate synthesis. Pharmaceutical innovation, including new formulations and delivery systems, also necessitates a steady supply of these chemical building blocks.

The global burden of mental illnesses, such as schizophrenia and bipolar disorder, is a significant driver. Increased awareness and diagnosis contribute to a higher demand for effective treatments like quetiapine. Stressful lifestyles, socioeconomic factors, and aging populations are all contributing to the rising prevalence of mental health disorders.

The expiration of patents on branded quetiapine has opened the market to generic drug manufacturers. This has led to increased competition and a focus on cost-effective production, which directly impacts the demand for affordable intermediate chemicals. Pharmaceutical companies are continuously researching and developing new formulations of quetiapine, such as extended-release versions and novel delivery systems. This research and development activity requires a consistent supply of high-quality intermediates.

The increased prevalence of mental health disorders directly drives pharmaceutical demand for quetiapine, thus escalating the need for its intermediate chemicals. The push for cost-effective generic drug manufacturing compels pharma companies to source these intermediates efficiently. Pharmaceutical R&D efforts focusing on novel quetiapine formulations and delivery systems further contribute to the rising demand for these crucial chemical building blocks.

The Asia-Pacific region is experiencing rapid growth in its pharmaceutical sector, driven by increasing healthcare expenditure and a rising prevalence of mental health disorders, significantly boosting quetiapine demand. The region's strong focus on generic drug manufacturing, aimed at providing affordable medications, directly amplifies the need for cost-effective quetiapine intermediates. Additionally, increasing investments in local pharmaceutical research and development across APAC further contribute to the growing demand for these crucial chemical precursors.

Quetiapine Intermediate Chemicals Market Report Highlights:

  • Based on end use, the pharmaceuticals segment is expected to have the largest revenue share of 85.5% in 2024. The rising prevalence of mental health disorders, such as schizophrenia and bipolar disorder, is driving increased demand for quetiapine, consequently boosting the need for its intermediate chemicals.
  • Based on product, the Dibenzo[b,f][1,4]thiazepin 11 (10 H)-one segment accounted for the largest revenue share of 35.2% in 2024 and is expected to continue to dominate the industry over the forecast period. It is a fundamental intermediate in quetiapine synthesis, forming the core ring structure. Its production efficiency directly impacts quetiapine output, thus influencing the demand for all upstream intermediates
  • Based on region, Asia-Pacific dominated with a revenue share of 50.7% in 2024. The rapidly growing pharmaceutical industry in the Asia-Pacific region, driven by increasing healthcare expenditure and a rising prevalence of mental health disorders, fuels demand for quetiapine intermediates.
  • In December 2024, Ami Organics Ltd. commenced construction of a second production line at its Cangzhou facility in Hebei Province, China, to manufacture the multifunctional additive Nylostab S-EED. This expansion, in partnership with Beijing Tiangang Auxiliary Co., Ltd., aims to meet the increasing demand from China's nylon industry, particularly in the textiles, automotive, and packaging sectors.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1. Information Analysis
    • 1.3.2. Market Formulation & Data Visualization
    • 1.3.3. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. Market Variables, Trends, and Scope

  • 3.1. Global Quetiapine Intermediate Chemicals Market Outlook
  • 3.2. Value Chain Analysis
    • 3.2.1. Raw Material Outlook
    • 3.2.2. Industrial Refrigeration/Product Outlook
    • 3.2.3. Sales Channel Analysis
  • 3.3. Price Trend Analysis
    • 3.3.1. Factors Influencing Prices
  • 3.4. Regulatory Framework
    • 3.4.1. Standards & Compliances
  • 3.5. Market Dynamics
    • 3.5.1. Market Driver Analysis
    • 3.5.2. Market Restraint Analysis
    • 3.5.3. Market Challenges Analysis
    • 3.5.4. Market Opportunity Analysis
  • 3.6. Porter's Five Forces Analysis
    • 3.6.1. Bargaining Power of Suppliers
    • 3.6.2. Bargaining Power of Buyers
    • 3.6.3. Threat of Substitution
    • 3.6.4. Threat of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTLE Analysis
    • 3.7.1. Political
    • 3.7.2. Economic
    • 3.7.3. Social Landscape
    • 3.7.4. Product
    • 3.7.5. Environmental
    • 3.7.6. Legal

Chapter 4. Quetiapine Intermediate Chemicals Market: Product Estimates & Trend Analysis

  • 4.1. Quetiapine Intermediate Chemicals Market: Product Movement Analysis, 2024 & 2030
  • 4.2. 1-[2-(2-Hydroxyethoxy) ethyl]Piperazine
    • 4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3. Dibenzo[b,f][1,4]thiazepin 11 (10 H)-one
    • 4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4. Other Products
    • 4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Quetiapine Intermediate Chemicals Market: End Use Estimates & Trend Analysis

  • 5.1. Quetiapine Intermediate Chemicals Market: End Use Movement Analysis, 2024 & 2030
  • 5.2. Pharmaceuticals
    • 5.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.3. Other End Uses
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Quetiapine Intermediate Chemicals Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Analysis, 2024 & 2030
  • 6.2. North America
    • 6.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
    • 6.2.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.2.4. U.S.
      • 6.2.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.2.4.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.2.4.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.2.5. Canada
      • 6.2.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.2.5.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.2.5.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.2.6. Mexico
      • 6.2.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.2.6.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.2.6.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
    • 6.3.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.3.4. Germany
      • 6.3.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.3.4.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.3.4.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.3.5. UK
      • 6.3.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.3.5.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.3.5.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.3.6. France
      • 6.3.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.3.6.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.3.6.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.3.7. Italy
      • 6.3.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.3.7.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.3.7.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.3.8. Spain
      • 6.3.8.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.3.8.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.3.8.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
    • 6.4.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.4.4. China
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.4.4.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.4.4.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.4.5. India
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.4.5.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.4.5.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.4.6. Japan
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.4.6.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.4.6.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.4.7. South Korea
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.4.7.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.4.7.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
    • 6.5.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.5.4. Brazil
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.5.4.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.5.4.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.5.5. Argentina
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.5.5.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.5.5.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • 6.6. Middle East & Africa
    • 6.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
    • 6.6.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.6.4. Saudi Arabia
      • 6.6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.6.4.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.6.4.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
    • 6.6.5. South Africa
      • 6.6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.6.5.2. Market estimates and forecasts, by product, 2018 - 2030 (USD Million)
      • 6.6.5.3. Market estimates and forecasts, by end use, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Market Positioning Analysis, 2024
  • 7.5. Strategy Mapping
  • 7.6. Company Profiles/Listing
    • 7.6.1. Merck KGaA
      • 7.6.1.1. Company Overview
      • 7.6.1.2. Financial Performance
      • 7.6.1.3. Product Benchmarking
    • 7.6.2. Shreeneel Chemicals
      • 7.6.2.1. Company Overview
      • 7.6.2.2. Financial Performance
      • 7.6.2.3. Product Benchmarking
    • 7.6.3. Emeron Electric Co.
      • 7.6.3.1. Company Overview
      • 7.6.3.2. Financial Performance
      • 7.6.3.3. Product Benchmarking
    • 7.6.4. Luye Pharma Group
      • 7.6.4.1. Company Overview
      • 7.6.4.2. Financial Performance
      • 7.6.4.3. Product Benchmarking
    • 7.6.5. Argana Group
      • 7.6.5.1. Company Overview
      • 7.6.5.2. Financial Performance
      • 7.6.5.3. Product Benchmarking
    • 7.6.6. IOL Chemicals & Pharmaceuticals Ltd
      • 7.6.6.1. Company Overview
      • 7.6.6.2. Financial Performance
      • 7.6.6.3. Product Benchmarking
    • 7.6.7. AR Lifesciences
      • 7.6.7.1. Company Overview
      • 7.6.7.2. Financial Performance
      • 7.6.7.3. Product Benchmarking
    • 7.6.8. ALLCHEM LIFESCIENCE PVT. LTD.
      • 7.6.8.1. Company Overview
      • 7.6.8.2. Financial Performance
      • 7.6.8.3. Product Benchmarking
    • 7.6.9. AstraZeneca
      • 7.6.9.1. Company Overview
      • 7.6.9.2. Financial Performance
      • 7.6.9.3. Product Benchmarking
    • 7.6.10. Shreeneel Chemicals
      • 7.6.10.1. Company Overview
      • 7.6.10.2. Financial Performance
      • 7.6.10.3. Product Benchmarking
    • 7.6.11. Aether Industries
      • 7.6.11.1. Company Overview
      • 7.6.11.2. Financial Performance
      • 7.6.11.3. Product Benchmarking
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제